Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022026645 - TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)

Publication Number WO/2022/026645
Publication Date 03.02.2022
International Application No. PCT/US2021/043611
International Filing Date 29.07.2021
IPC
A61K 31/416 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4151,2-Diazoles
416condensed with carbocyclic ring systems, e.g. indazole
A61K 31/437 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
4353ortho- or peri-condensed with heterocyclic ring systems
437the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61P 11/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
CPC
A61K 31/513
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
513having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 31/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
16for influenza or rhinoviruses
Applicants
  • MELIOR PHARMACEUTICALS I, INC. [US]/[US]
Inventors
  • REAUME, Andrew G.
  • SMAGIN, Gennady
Agents
  • LEGAARD, Paul K.
Priority Data
63/058,77430.07.2020US
63/146,56105.02.2021US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
(FR) TRAITEMENT DU SYNDROME DE DÉTRESSE RESPIRATOIRE AIGUË
Abstract
(EN) Methods of preventing, delaying, or reducing the severity of pulmonary extravasation, pulmonary edema, pneumonia, fluid in the lung, acute respiratory distress syndrome, plasma extravasation, and/or pulmonary conditions that develop as a result of hypercytokinemia (cytokine storm syndrome) in a mammal having a medical condition by administering a lyn kinase activator are provided herein.
(FR) L'invention concerne des procédés de prévention, de retardement ou de réduction de la gravité de l'extravasation pulmonaire, d'un oedème pulmonaire, d'une pneumonie, de la présence de fluide dans les poumons, d'un syndrome de détresse respiratoire aiguë, d'une extravasation de plasma et/ou de troubles pulmonaires qui se développent suite à l'hypercytokinémie (syndrome de tempête de cytokine) chez un mammifère présentant un trouble médical par l'administration d'un activateur de lyn kinase.
Latest bibliographic data on file with the International Bureau